Status: Recruiting
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
Participants needed: 100
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: University of Colorado, DenverUpdated: Feb 20, 2026Locations: 1
Eligibility criteria
Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted t... [+21]
Concurrent health problem which would preclude tissue biopsy (e.g. hemophilia or... [+4]